News & Updates

Show Multimedia Only
Tislelizumab improves survival in advanced gastric/gastro-oesophageal junction adenocarcinoma
Tislelizumab improves survival in advanced gastric/gastro-oesophageal junction adenocarcinoma
04 Jun 2024 byStephen Padilla

First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.

Tislelizumab improves survival in advanced gastric/gastro-oesophageal junction adenocarcinoma
04 Jun 2024
Low-dose aspirin for AMD prevention? ASPREE data show no benefit
Low-dose aspirin for AMD prevention? ASPREE data show no benefit
01 Jun 2024 byJairia Dela Cruz

Use of aspirin at 100 mg per day proved unsuccessful at reducing the incidence of age-related macular degeneration (AMD) in a large cohort of older healthy individuals, according to medium-term data from the AMD substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial.

Low-dose aspirin for AMD prevention? ASPREE data show no benefit
01 Jun 2024